FDA

Phase 3 Clinical Trial Demonstrates 44% Reduction in Oncology Recurrence for mRNA Therapeutic Vaccine

Biomedical researchers report significant disease-free survival metrics in late-stage melanoma trials, prompting expedited regulatory review requests.